Merck & Co., Inc. Interest Expense Nonoperating
Merck & Co., Inc. (MRK) reported Interest Expense Nonoperating of $525.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-07
- Merck & Co., Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $525.00M, a 72.13% increase year-over-year.
- Merck & Co., Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $479.00M, a 53.04% increase year-over-year.
- Merck & Co., Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $411.00M, a 25.30% increase year-over-year.
- Merck & Co., Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $327.00M, a 0.91% decline year-over-year.
- Merck & Co., Inc. interest expense nonoperating for fiscal 2025 was $1.36B, a 6.77% increase from fiscal 2024.
- Merck & Co., Inc. interest expense nonoperating for fiscal 2024 was $1.27B, a 10.91% increase from fiscal 2023.
- Merck & Co., Inc. interest expense nonoperating for fiscal 2023 was $1.15B, a 19.13% increase from fiscal 2022.
- Merck & Co., Inc. interest expense nonoperating for fiscal 2022 was $962.00M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $525.00M 10-Q · filed 2026-08-07 | $1.00B 10-Q · filed 2026-08-07 | $1.42B derived: sum of 3 quarters · filed 2026-08-07 | $1.74B derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $479.00M 10-Q · filed 2026-05-04 | $890.00M derived: sum of 2 quarters · filed 2026-05-04 | $1.22B derived: sum of 3 quarters · filed 2026-05-04 | $1.52B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $411.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $738.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.04B derived: sum of 3 quarters · filed 2026-08-07 | $1.36B 10-K · filed 2026-02-24 |
| 2025-09-30 | $327.00M 10-Q · filed 2025-11-05 | $632.00M derived: sum of 2 quarters · filed 2026-08-07 | $946.00M 10-Q · filed 2025-11-05 | $1.27B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $305.00M 10-Q · filed 2026-08-07 | $618.00M 10-Q · filed 2026-08-07 | $946.00M derived: sum of 3 quarters · filed 2026-08-07 | $1.28B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $313.00M 10-Q · filed 2026-05-04 | $641.00M derived: sum of 2 quarters · filed 2026-05-04 | $971.00M derived: sum of 3 quarters · filed 2026-05-04 | $1.28B derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $328.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $658.00M derived: sum of 2 quarters · filed 2026-02-24 | $968.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.27B 10-K · filed 2026-02-24 |
| 2024-09-30 | $330.00M 10-Q · filed 2025-11-05 | $640.00M derived: sum of 2 quarters · filed 2025-11-05 | $943.00M 10-Q · filed 2025-11-05 | $1.25B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $310.00M 10-Q · filed 2025-08-05 | $613.00M 10-Q · filed 2025-08-05 | $923.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.24B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $303.00M 10-Q · filed 2025-05-02 | $613.00M derived: sum of 2 quarters · filed 2026-02-24 | $930.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.21B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $310.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $627.00M derived: sum of 2 quarters · filed 2026-02-24 | $904.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.15B 10-K · filed 2026-02-24 |
| 2023-09-30 | $317.00M 10-Q · filed 2024-11-06 | $594.00M derived: sum of 2 quarters · filed 2024-11-06 | $836.00M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $277.00M 10-Q · filed 2024-08-05 | $519.00M 10-Q · filed 2024-08-05 | ||
| 2022-12-31 | $962.00M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |